piperidines and Scleritis

piperidines has been researched along with Scleritis* in 2 studies

Other Studies

2 other study(ies) available for piperidines and Scleritis

ArticleYear
New Potential Weapons for Refractory Scleritis in the Era of Targeted Therapy.
    Mediators of inflammation, 2020, Volume: 2020

    To assess the efficacy of biologic drugs, beyond tumor necrosis factor- (TNF-). Fourteen patients (19 eyes) were enrolled in the study. Scleritis inflammatory grading significantly improved from baseline to 3 months (. Our results, though limited to a low number of patients, highlight the effectiveness of different biologic therapies in the treatment of noninfectious refractory scleritis, showing to control scleral inflammation and allowing a significant reduction in the number of relapses.

    Topics: Abatacept; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Female; Humans; Immune System; Inflammation; Interleukin 1 Receptor Antagonist Protein; Male; Middle Aged; Ophthalmology; Piperidines; Pyrimidines; Recurrence; Retrospective Studies; Rituximab; Scleritis; Treatment Outcome

2020
Tofacitinib in recalcitrant scleritis: First case report from India.
    Indian journal of ophthalmology, 2020, Volume: 68, Issue:9

    A 65-year-old male presented with redness and pain associated with active necrotizing scleritis in the left eye. He was started on mycophenolate mofetil and oral corticosteroids, to which there was no response detected after 4 weeks. A rheumatology opinion was sought and he was started on tofacitinib, after which there was dramatic clinical improvement. Patients refractory to conventional immunosuppressive therapy can benefit from the new class of immunosuppressive agents, JAK/STAT kinase inhibitors.

    Topics: Aged; Humans; Immunosuppressive Agents; India; Male; Piperidines; Pyrimidines; Pyrroles; Scleritis

2020